Pharmacogenomics and stomach cancer

Pharmacogenomics

Volumn 5, Issue 6, 2004, Pages 627-641

  Toffoli, Giuseppe ^a   Cecchin, Erika ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

5 fluorouracil; Anthracyclines; Gastric; Irinotecan; Methotrexate; Mitomycin C; Pharmacogenetics; Platinum; Polymorphism; Taxanes

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; ANTHRACYCLINE DERIVATIVE; CAPECITABINE; CISPLATIN; DAUNORUBICIN; DIGOXIN; DIHYDROFLUOROURACIL; DIHYDROFOLIC ACID; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLOXURIDINE PHOSPHATE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METHOTREXATE; METHYLENETETRAHYDROFOLIC ACID; MITOMYCIN C; OXALIPLATIN; PACLITAXEL; PHENYTOIN; PROTEINASE INHIBITOR; TAXANE DERIVATIVE; TEGAFUR; TETRAHYDROFOLIC ACID; THYMIDINE PHOSPHATE; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DNA INTERACTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG SENSITIVITY; EVIDENCE BASED MEDICINE; GENE TARGETING; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIVIDUALIZATION; INTRACELLULAR TRANSPORT; OPTIMAL DRUG DOSE; PHARMACOGENOMICS; REVIEW; SIDE EFFECT; STOMACH CANCER; TREATMENT PLANNING;

ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; CLINICAL TRIALS; HUMANS; PHARMACOGENETICS; STOMACH NEOPLASMS; TAXOIDS;

EID: 4544388467     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.5.6.627     Document Type: Review

References (103)

1. Mari E, Floriani I, Tinazzi A et al.: Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann. Oncol. 11(7), 837-843 (2000).
2. Schoffski P: New drugs for treatment of gastric cancer. Ann. Oncol. 13(Suppl. 4),13-22 (2002).
3. Macdonald JS, Smalley SR, Benedetti J et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med. 345(10), 725-730 (2001).
4. Evans WE, McLeod HL: Pharmacogenomics - drug disposition, drug targets, and side effects. N. Engl. J. Med. 348(6), 538-549 (2003).
5. Danenberg PV: Thymidylate synthetase - a target enzyme in cancer chemotherapy. Biochim. Biophys. Acta 473(2), 73-92 (1977).
6. Heidelberger C, Chaudhuri NK, Danneberg P et al.: Fluorinated pyrimidines, a new class of tumor-inhibitory compounds. Nature 179(4561), 663-666 (1957).
7. Metzger R, Leichman CG, Danenberg KD et al.: ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J. Clin. Oncol. 16(1), 309-316 (1998).
8. Yeh KH, Shun CT, Chen CL et al.: High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy. Cancer 82(9), 1626-1631 (1998).
9. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K: Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct. Funct. 20(3), 191-197 (1995).
10. Pullarkat ST, Stoehlmacher J, Ghaderi V et al.: Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J. 1(1), 65-70 (2001).
11. Iacopetta B, Grieu F, Joseph D, Elsaleh H: A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br. J. Cancer 85(6), 827-830 (2001).
12. Villafranca E, Okruzhnov Y, Dominguez MA et al.: Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J. Clin. Oncol. 19(6), 1779-1786 (2001).
13. Zinzindohoue F, Ferraz JM, Laurent-Puig P: Thymidylate synthase promoter polymorphism. J. Clin. Oncol. 19(14), 3442 (2001).
14. Ishida Y, Kawakami K, Tanaka Y, Kanehira E, Omura K, Watanabe G: Association of thymidylate synthase gene polymorphism with its mRNA and protein expression and with prognosis in gastric cancer. Anticancer Res. 22(5), 2805-2809 (2002).
15. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei D, Groshen S, Lenz HJ: Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer. Int. J. Colorectal Dis. 17(1), 46-49 (2002).
16. Tsuji T, Hidaka S, Sawai T et al.: Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer. Clin. Cancer Res. 10(Part 1), 3700-3704 (2003).
17. Mandola MV, Stoehlmacher J, Muller-Weeks S et al.: A novel single nucleotide polymorphism within the 5′ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res. 63(11), 2898-2904 (2003 ).
18. Kawakami K, Watanabe G: Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res. 63(18), 6004-6007 (2003).
19. Ulrich CM, Bigler J, Velicer CM, Greene EA, Farin FM, Potter JD: Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol. Biomarkers Prev. 9(12), 1381-1385 (2000).
20. Mandola MV, Stoehlmacher J, Zhang W et al.: A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 14(5), 319-327 (2004).
21. Diasio RB, Harris BE: Clinical pharmacology of 5-fluorouracil. Clin. Pharmacokinet. 16(4), 215-237 (1989).
22. Chazal M, Etienne MC, Renee N, Bourgeon A, Richelme H, Milano G: Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver. Clin. Cancer Res. 2(3), 507-510 (1996).
23. Fleming RA, Milano G, Thyss A et al.: Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res. 52(10), 2899-2902 (1992).
24. Takabayashi A, Iwata S, Kawai Y et al.: Dihydropyrimidine dehydrogenase activity and mRNA expression in advanced gastric cancer analysed in relation to effectiveness of preoperative 5-fluorouracil-based chemotherapy. Int. J. Oncol. 17(5), 889-895 (2000).
25. Ridge SA, Sludden J, Wei X et al.: Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer. Br. J. Cancer 77(3), 497-500 (1998).
26. Wei X, McLeod HL, McMurrough J, Gonzalez FJ, Fernandez-Salguero P: Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J. Clin. Invest. 98(3), 610-615 (1996).
27. Van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH: High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 12(7), 555-558 (2002).
28. Etienne MC, Ilc K, Formento JL et al.: Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity. Br. J. Cancer 90(2), 526-534 (2004).
29. Sohn KJ, Croxford R, Yates Z, Lucock M, Kim YI: Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J. Natl. Cancer Inst. 96(2), 134-144 (2004).
30. Cohen V, Panet-Raymond V, Sabbaghian N, Morin I, Batist G, Rozen R: Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin. Cancer Res. 9(5), 1611-1615 (2003).
31. Nishigaki Y, Marti R, Copeland WC, Hirano M: Site-specific somatic mitochondrial DNA point mutations in patients with thymidine phosphorylase deficiency. J. Clin. Invest. 111(12), 1913-1921 (2003).
32. Brinkmann U, Eichelbaum M: Polymorphisms in the ABC drug transporter gene MDR1. Pharmacogenomics J. 1(1), 59-64 (1993).
33. Hoffmeyer S, Burk O, von Richter O et al.: Functional polymorphisms of the human multi-drug resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 97(7), 3473-3478 (2000).
34. Kerb R, Aynacioglu AS, Brockmoller J et al.: The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J. 1(3), 204-210 (1904).
35. Illmer T, Schuler US, Thiede C et al.: MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukaemia patients. Cancer Res. 62(17), 4955-4962 (2002).
36. Kafka A, Sauer G, Jaeger C et al.: Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int. J. Oncol. 22(5), 1117-1121 (2003).
37. Schuurhuis GJ, Broxterman HJ, Ossenkoppele GJ et al.: Functional multi-drug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-β-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukaemia. Clin. Cancer Res. 1(1), 81-93 (1995 ).
38. Toh S, Wada M, Uchiumi T et al.: Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome. Am. J. Hum. Genet. 64(3), 739-746 (1999).
39. Mor-Cohen R, Zivelin A, Rosenberg N, Shani M, Muallem S, Seligsohn U: Identification and functional analysis of two novel mutations in the multi-drug resistance protein 2 gene in Israeli patients with Dubin-Johnson syndrome. J. Biol. Chem. 276(40), 36923-36930 (2001).
40. Itoda M, Saito Y, Soyama A et al.: Polymorphisms in the ABCC2 (cMOAT/MRP2) gene found in 72 established cell lines derived from Japanese individuals: an association between single nucleotide polymorphisms in the 5′-untranslated region and exon 28. Drug Metab. Dispos. 30(4), 363-364 (2002).
41. Smith CA, Smith G, Wolf CR: Genetic polymorphisms in xenobiotic metabolism. Eur. J. Cancer 30A(13), 1921-1935 (1994).
42. Pemble S, Schroeder KR, Spencer SR et al.: Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem. J. 300(Part 1), 271-276 (1994).
43. Ambrosone CB, Sweeney C, Coles BF et al.: Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer. Cancer Res. 61(19), 7130-7135 (2001).
44. Traver RD, Horikoshi T, Danenberg KD et al.: NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res. 52(4), 797-802 (1992).
45. Goldberg ZI, Cummings BJ, Chapman WB, Klamut HJ, Rauth AM: Role of a DT-diaphorase mutation in the response of anal canal carcinoma to radiation, 5-fluorouracil, and mitomycin C. Int. J. Radiat. Oncol. Biol. Phys. 42(2), 331-334 (1998).
46. Phillips RM, Burger AM, Fiebig HH, Double JA: Genotyping of NAD(P)H:quinone oxidoreductase (NQO1) in a panel of human tumor xenografts: relationship between genotype status, NQO1 activity and the response of xenografts to mitomycin C chemotherapy in vivo(1). Biochem. Pharmacol. 62(10), 1371-1377 (2001).
47. Fleming RA, Drees J, Loggie BW et al.: Clinical significance of a NAD(P)H: quinone oxidoreductase 1 polymorphism in patients with disseminated peritoneal cancer receiving intraperitoneal hyperthermic chemotherapy with mitomycin C. Pharmacogenetics 12(1), 31-37 (2002).
48. Chiusolo P, Reddiconto G, Casorelli I et al.: Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukaemia patients intolerant to methotrexate. Ann. Oncol. 13(12), 1915-1918 (2002).
49. Meyer K, Fredriksen A, Ueland PM: High-level multiplex genotyping of polymorphisms involved in folate or homocysteine metabolism by matrix-assisted laser desorption/ionization mass spectrometry. Clin. Chem. 50(2), 391-402 (2004).
50. Trinh BN, Ong CN, Coetzee GA, Yu MC, Laird PW: Thymidylate synthase: a novel genetic determinant of plasma homocysteine and folate levels. Hum. Genet. 111(3), 299-302 (2002).
51. Toffoli G, Russo A, Innocenti F et al.: Effect of methylenetetrahydrofolate reductase 677C-> T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Int. J. Cancer 103(3), 294-299 (2003).
52. Urano W, Taniguchi A, Yamanaka H et al.: Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 12(3), 183-190 (2002).
53. Ulrich CM, Yasui Y, Storb R et al.: Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 98(1), 231-234 (2001).
54. Robien K, Schubert MM, Bruemmer B, Lloid ME, Potter JD, Ulrich CM: Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukaemia. J. Clin. Oncol. 22(7), 1268-1275 (2004).
55. Rothem L, Ifergan I, Kaufman Y, Priest DG, Jansen G, Assaraf YG: Resistance to multiple novel antifolates is mediated via defective drug transport resulting from clustered mutations in the reduced folate carrier gene in human leukaemia cell lines. Biochem. J. 367(Part 3), 741-750 (2002).
56. Chango A, Emery-Fillon N, de Courcy GP et al.: A polymorphism (80G->A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol. Genet. Metab. 70(4), 310-315 (2000).
57. Kishi S, Griener J, Cheng C et al.: Homocysteine, pharmacogenetics, and neurotoxicity in children with leukaemia. J. Clin. Oncol. 21(16), 3084-3091 (2003).
58. Oguri T, Fujiwara Y, Katoh O et al.: Glutathione S-transferase-pi gene expression and platinum drug exposure in human lung cancer. Cancer Lett. 156(1), 93-99 (2000).
59. Zimniak P, Nanduri B, Pikula S et al.: Naturally-occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymic properties. Eur. J. Biochem. 224(3), 893-899 (1994).
60. Stoehlmacher J, Park DJ, Zhang W et al.: Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J. Natl. Cancer Inst. 94(12), 936-942 (2002).
61. Medeiros R, Pereira D, Afonso N et al.: Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome. Int. J. Clin. Oncol. 8(3), 156-161 (2003).
62. Levenson VV, Davidovich IA, Roninson IB: Pleiotropic resistance to DNA-interactive drugs is associated with increased expression of genes involved in DNA replication, repair, and stress response. Cancer Res. 60(18), 5027-5030 (2000).
63. Goode EL, Ulrich CM, Potter JD: Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev. 11(12), 1513-1530 (2002).
64. Chen ZP, Malapetsa A, Monks A et al.: Nucleotide excision repair protein levels vis-a-vis anticancer drug resistance in 60 human tumor cell lines. Ai Zheng 21(3), 233-239 (2002).
65. Shen MR, Jones IM, Mohrenweiser H: Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res. 58(4), 604-608 (1998).
66. Hou SM, Falt S, Angelini S et al.: The XPD variant alleles are associated with increased aromatic DNA adduct level and lung cancer risk. Carcinogenesis 23(4), 599-603 (2002).
67. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ: A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res. 61(24), 8654-8658 (2001).
68. Guichard S, Arnould S, Hennebelle I, Bugat R, Canal P: Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo. Anticancer Drugs 12(9), 741-751 (2001).
69. Yu JJ, Mu C, Lee KB et al.: A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues. Mutat. Res. 382(1-2), 13-20 (1997).
70. Hu JJ, Smith TR, Miller MS, Mohrenweiser HW, Golden A, Case LD: Amino acid substitution variants of APE1 and XRCC1 genes associated with ionizing radiation sensitivity. Carcinogenesis 22(6), 917-922 (2001).
71. Wang Y, Spitz MR, Zhu Y, Dong Q, Shete S, Wu X: From genotype to phenotype: correlating XRCC1 polymorphisms with mutagen sensitivity. DNA Repair (Amst.) 2(8), 901-908 (2003).
72. Smith TR, Miller MS, Lohman K et al.: Polymorphisms of XRCC1 and XRCC3 genes and susceptibility to breast cancer. Cancer Lett. 190(2), 183-190 (2003).
73. Stoehlmacher J, Ghaderi V, Iobal S et al.: A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res. 21(4B), 3075-3079 (2001).
74. Mathijssen RH, Marsh S, Karlsson MO et al.: Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin. Cancer Res. 9(9), 3246-3253 (2003).
75. Itamochi H, Kigawa J, Sultana H et al.: Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary. Jpn. J. Cancer Res. 93(6), 723-728 (2002).
76. Yokoyama Y, Sato S, Fukushi Y, Sakamoto T, Futagami M, Saito Y: Significance of multi-drug resistant proteins in predicting chemotherapy response and prognosis in epithelial ovarian cancer. J. Obstet. Gynaecol. Res. 25(6), 387-394 (1999).
77. Arts HJ, Katsaros D, de Vries EG et al.: Drug resistance-associated markers P-glycoprotein, multi-drug resistance-associated protein 1, multi-drug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma. Clin. Cancer Res. 5(10), 2798-2805 (1999).
78. Bellincampi L, Ballerini S, Bernardini S et al.: Glutathione transferase P1 polymorphism in neuroblastoma studied by endonuclease restriction mapping. Clin. Chem. Lab Med. 39(9), 830-835 (2001).
79. Rivory LP, Bowles MR, Robert J, Pond SM: Conversion of irinotecan (CPT-11) to its active metabolite, Tethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem. Pharmacol. 52(7), 1103-1111 (1996).
80. Ketterman AJ: Polymorphisms of human liver carboxylesterases. Biochem. Soc. Trans. 19(1), 306S (1991).
81. Kuehl P, Zhang J, Lin Y et al.: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27(4), 383-391 (2001).
82. Iyer L, King CD, Whitington PF et al.: Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J. Clin. Invest. 101(4), 847-854 (1998).
83. Ciotti M, Basu N, Brangi M, Owens IS: Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus. Biochem. Biophys. Res. Commun 260(1), 199-202 (1999).
84. Monaghan G, Ryan M, Seddon R, Hume R, Burchell B: Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 347(9001), 578-581 (1996).
85. Ando Y, Saka H, Ando M et al.: Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 60(24), 6921-6926 (2000).
86. Ando Y, Ueoka H, Sugiyama T, Ichiki M, Shimokata K, Hasegawa Y: Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan. Ther. Drug Monit. 24(1), 111-116 (2002).
87. Iyer L, Das S, Janisch L et al.: UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2(1), 43-47 (2002).
88. Sai K, Saeki M, Saito Y et al.: UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin. Pharmacol. Ther. 75(6), 501-515 (2004).
89. Innocenti F, Undevia SD, Iyer L et al.: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. 22(8), 1382-1388 (2004).
90. Gagne JF, Montminy V, Belanger P, Journault K, Gaucher G, Guillemette C: Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol. Pharmacol. 62(3), 608-617 (2002).
91. Iyer L, Ramirez J, Shepard DR et al.: Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice. Cancer Chemother. Pharmacol. 49(4), 336-341 (2002).
92. Kumar GN, Walle UK, Walle T: Cytochrome P450 3A-mediated human liver microsomal taxol 6 α-hydroxylation. J. Pharmacol. Exp. Ther. 268(3), 1160-1165 (1994).
93. Dai D, Zeldin DC, Blaisdell JA et al.: Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11(7), 597-607 (2001).
94. Goh BC, Lee SC, Wang LZ et al.: Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J. Clin. Oncol. 20(17), 3683-3690 (2002).
95. Kamazawa S, Kigawa J, Kanamori Y et al.: Multi-drug resistance gene-1 is a useful predictor of paclitaxel-based chemotherapy for patients with ovarian cancer. Gynecol. Oncol. 86(2), 171-176 (2002).
96. Yeh JJ, Hsu WH, Wang JJ, Ho ST, Kao A: Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer with P-glycoprotein expression. Respiration 70(1), 32-35 (2003).
97. Marsh S, McLeod HL: Cancer pharmacogenetics. Br. J. Cancer 90(1), 8-11 (2004).
98. Raida M, Schwabe W, Hausler P et al.: Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. Clin. Cancer Res. 7(9), 2832-2839 (2001).
99. Berlin K, Gut IG: Analysis of negatively 'charge tagged' DNA by MALDI-TOF MS. Rapid Commun. Mass Spectrom. 13, 1339-1343. 1999.
100. Landi S, Gemignani F, Gioia-Patricola L, Chabrier A, Canzian F: Evaluation of a microarray for genotyping polymorphisms related to xenobiotic metabolism and DNA repair. Biotechniques 35(4), 816-817 (2003).
101. Kakeji Y, Maehara Y, Sumiyoshi Y, Oda S, Emi Y: Angiogenesis as a target for gastric cancer. Surgery 131(Suppl. 1), S48-S54 (2002).
102. Lynch TJ, Bell DW, Sordella R et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350(21), 2129-2139 (2004).
103. Cyranoski D: Biologists take tentative steps towards bespoke cancer drugs. Nature 423(6937), 209 (2003).